Cell-Easy – reducing stem cells manufacturing cost for cell therapies

Cell-Easy is a cell therapy Contract Development and Manufacturing Organization (CDMO) for preclinical and clinical drug development projects.

Cell-Easy’s aspiration is to dramatically reduce stem cell manufacturing cost, starting with ASC (historical and local strong expertise), to change the affordability challenge currently met by Cell Therapies. Its ASC production process was designed using QbD approach and economical study (Manufacturing Cost model simulation) to ensure cell quality, scalability, compatibility with GMP requirements and economic viability for the entire clinical development INCLUDING the commercialization.

European leading CDMO company specialized in large volume industrialized production of GMP approved cell products

Cell-Easy’s team is committed to its customers to develop & produce ATMPs for clinical advanced therapies. Its ambition combines analytical and process innovations to provide cGMP cells with extended characterization (safety, identity, and performance). Cell-Easy’s experience in stem cells has grown from its original ambition: to make cell therapy accessible to as many patients as possible, by combining an allogeneic approach with a high-performance culture process. Its MSC production process has been designed using a QbD approach and an economic study (simulation of the manufacturing cost model) to ensure cell quality, scalability, compatibility with GMP requirements and economic viability for the entire clinical development, including commercialization.

Analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in Cell Therapy, Cell-Easy offers customized process development, GMP manufacturing and unique analytical services for adult stem cells (MSCs, iPSCs and Exosome) and immune cells (engineered CAR-T,-NK…cells, and non-engineered cells) in Regenerative Medicine and Immuno-oncology fields.

Cell-Easy facilities comprise 350 sqm of qualified controlled environment suites optimized to develop Manufacturing and Analytical Process, proceed to environmental and material Quality Control and execute cGMP Manufacturing, Fill&Finish, long-term Storage of ATMPs compliant with all the requirements of Regulatory Standards and cGMP guidelines.

Cell-Easy is a recent and fast-growing biotech startup based in Toulouse, France. The Cell-Easy Management team and all collaborators have a strong expertise in the Development and Manufacturing of innovative cell-based therapies.

More info : https://www.cell-easy.com/

Biophytis – therapeutics to slow down the degenerative processes associated with aging

Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.

Biophytis - therapeutics to slow down the degenerative processes associated with aging

Biophytis SA, founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory. The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute

Its lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

Biophytis also has preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease. Spinal Muscular Atrophy is a rare progressive neurodegenerative disease that robs an individual of the ability to walk, eat and breathe. SMA is the leading genetic cause of death in infants. Symptoms may appear in the first 6 months of life (type 1, the most severe and common), in infancy (types 2 and 3) or in adulthood (type 4, the least common form). SMA affects 1 in 11,000 births in the United States each year, and about 1 in 50 Americans is a genetic carrier.

More info : www.biophytis.com

Keywords for Biophytis :

neuromuscular diseases, dry age-related macular degeneration, AMD, ophthalmology, infectious diseases, COVID19, Asthma, COPD, small molecule, sarcopenia, Stargardt disease, Duchenne muscular dystrophy , DMD, preclinical stage pharma company, clinical stage pharma company , Spinal Muscular Atrophy , rare diseases , aging

Cytoo – next generation HCS with physiologically relevant cellular models

Cytoo - next generation HCS with physiologically relevant cellular models

Continue reading

AgileBio – collaborative tools that enhance research productivity

AgileBio – collaborative tools that enhance research productivity

agilebio

Continue reading

DDI-Predictor – predict drug drug interactions mediated by cytochromes

DDI-Predictor – predict drug drug interactions mediated by cytochromes

ddi-predictor

Continue reading

Kromaton – centrifugal partition chromatography

KROMATON is an innovating firm pioneer in Centrifugal Partition Chromatography (CPC), or Countercurrent Chromatography (CCC), a liquid/liquid preparative chromatography technique.

Kromaton – centrifugal partition chromatography

Kromaton

Continue reading

IDD Biotech – differentiated therapeutic MAbs

IDD biotech aims to improve the life of patients by developing differentiated therapeutic MAbs for the pharmaceutical market with a pipeline of internally discovered product candidates and strategic collaborations with research institutes and pharmaceutical companies.

IDD Biotech – differentiated therapeutic MAbs

IDD Biotech

Continue reading

Poietis – 4D Bioprinting

Poietis is a biotech company whose mission is to design, develop and market innovative solutions based on 4D Bioprinting to support Researchers and Physicians in the emergence of personalized medicine.

Poietis – 4D Bioprinting

Poietis

Continue reading

Eyebrain – neurological and psychiatric diseases

The founding purpose of EyeBrain is to provide medicine as well as clinical research with innovative tools for the functional exploration and analysis of healthy and diseased brain activity. Eyebrain’s mission is to propose an aid to the diagnosis of diseases that are difficult to detect and apprehend.

Eyebrain – neurological and psychiatric diseases

eyebrain

Continue reading

Algosource Technologies – photosynthetic microalgae

Algosource Technologies, recognized as one of the major microalgae world expert, offers a full range of services from production engineering to industrial scale-up of microalgae. Its unique expertise covers the entire process of production and processing of microalgae and allows an integrated approach to its industrial customers.

Algosource Technologies – photosynthetic microalgae

Algosource technologies

Continue reading